0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessMetformin may be safer for use in CKD than previously considered and may lower the risk of death and cardiovascular events in individuals with stage 3 CKD.
David M. Charytan, Scott D. Solomon, Peter Ivanovich, Giuseppe Remuzzi, Mark E. Cooper, Janet B. McGill, Hans‐Henrik Parving, Patrick S. Parfrey, Ajay Singh, Emmanuel A. Burdmann, Andrew S. Levey, Kai‐Uwe Eckardt, John J.V. McMurray, Larry A. Weinrauch, Jiankang Liu, Brian Claggett, Eldrin F. Lewis, Marc A. Pfeffer (2019). Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. , 21(5), DOI: https://doi.org/10.1111/dom.13642.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2019
Authors
18
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1111/dom.13642
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
.webp){kind=avatar}
